Antisoma trial delivers positive returns

A mid-stage trial of Antisoma's AS1404 for prostate cancer demonstrated a higher rate of protein-specific antigen responses among volunteers in the study. Patients taking AS1404 with docetaxel chemotherapy recorded an average 57 percent PSA response rate compared to 35 percent for docetaxel chemotherapy alone. In addition, patients taking the combinational therapy demonstrated disease progression in 17 percent of cases compared to 29 percent for the solo therapy regimen.

"These positive data from our Phase II prostate cancer trial of AS1404 are a further important demonstration of the drug's effects," said CEO Glyn Edwards. "They complement the already positive survival, progression and response data already presented from our lung cancer trial, and show that the potential of AS1404 extends to two of the big four cancer indications."

- here's the report on Antisoma

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.